Flush With Cash, Tesaro Advances Rolapitant Toward NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Tesaro’s three-drug oncology program, including its lead NK-1 product for chemo-induced nausea and vomiting, is boosted by a recent raise from the public markets.
You may also be interested in...
Tesaro On Track For Mid-Year NDA Filing Of Oral CINV Candidate Rolapitant
While awaiting data from the third and final Phase III trial of the oral cancer supportive care candidate, Tesaro also will advance an I.V. formulation of rolapitant. Meanwhile, PARP inhibitor niraparib is in two Phase III trials in oncology indications, with a plan to seek other tumor types the compound might treat.
Tesaro’s Rolapitant Hits Primary Endpoints, But Still Disappoints
The oncology company’s nausea treatment was successful in late-stage trials, but Tesaro may have trouble differentiating the drug once it reaches the market due to a lack of evidence that it can compete with the current standard of care.
Tesaro’s Rolapitant Hits Primary Endpoints, But Still Disappoints
The oncology company’s nausea treatment was successful in late-stage trials, but Tesaro may have trouble differentiating the drug once it reaches the market due to a lack of evidence that it can compete with the current standard of care.